Cyclopharm Limited provided earnings guidance for the full year 2021. For the period, the company's revenue is expected to be between approximately AUD 17.5 million and AUD 18.0 million, representing growth of between 19% - 22% increase over the prior corresponding period.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.422 AUD | -0.87% | +2.34% | -26.10% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.10% | 101M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- CYC Stock
- News Cyclopharm Limited
- Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021